Provided herein are methods of treating cancers characterized by a high frequency of one or more suppressive immune cells, comprising administering a therapeutically effective amount of an enhancer of zeste homolog 2 (EZH2) inhibitor. Also provided are combination therapies using an EZH2 inhibitor and a second agent that is an immunomodulator.